
Michael Platten

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4668070/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	27.8	1,872
2	An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature, 2011, 478, 197-203.	27.8	1,514
3	Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncology, The, 2012, 13, 707-715.	10.7	980
4	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nature Reviews Clinical Oncology, 2021, 18, 170-186.	27.6	826
5	Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nature Reviews Drug Discovery, 2019, 18, 379-401.	46.4	805
6	Brain tumour cells interconnect to a functional and resistant network. Nature, 2015, 528, 93-98.	27.8	787
7	Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 14948-14953.	7.1	755
8	Lomustine and Bevacizumab in Progressive Glioblastoma. New England Journal of Medicine, 2017, 377, 1954-1963.	27.0	670
9	Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature, 2019, 565, 240-245.	27.8	637
10	A vaccine targeting mutant IDH1 induces antitumour immunity. Nature, 2014, 512, 324-327.	27.8	613
11	Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion. Cancer Research, 2012, 72, 5435-5440.	0.9	591
12	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncology, The, 2017, 18, 682-694.	10.7	586
13	Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature, 2014, 511, 184-190.	27.8	574
14	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology, 2020, 22, 1073-1113.	1.2	543
15	MGMT testing—the challenges for biomarker-based glioma treatment. Nature Reviews Neurology, 2014, 10, 372-385.	10.1	454
16	Treatment of Autoimmune Neuroinflammation with a Synthetic Tryptophan Metabolite. Science, 2005, 310, 850-855.	12.6	391
17	SD-208, a Novel Transforming Growth Factor Î ² Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells In vitro and In vivo. Cancer Research, 2004, 64, 7954-7961.	0.9	380
18	ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated―diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathologica, 2015, 129, 133-146.	7.7	378

#	Article	IF	CITATIONS
19	Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nature Medicine, 2018, 24, 1192-1203.	30.7	359
20	Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature, 2022, 603, 321-327.	27.8	343
21	Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathologica, 2018, 136, 181-210.	7.7	308
22	ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathologica, 2013, 126, 443-451.	7.7	304
23	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathologica, 2018, 136, 153-166.	7.7	298
24	Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors. Frontiers in Immunology, 2014, 5, 673.	4.8	284
25	IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathologica, 2015, 129, 867-873.	7.7	272
26	Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. Lancet Oncology, The, 2019, 20, 728-740.	10.7	271
27	Toll-Like Receptor Engagement Enhances the Immunosuppressive Properties of Human Bone Marrow-Derived Mesenchymal Stem Cells by Inducing Indoleamine-2,3-dioxygenase-1 via Interferon-β and Protein Kinase R Â. Stem Cells, 2009, 27, 909-919.	3.2	268
28	<i>MGMT</i> Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clinical Cancer Research, 2015, 21, 2057-2064.	7.0	264
29	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathologica, 2013, 126, 907-915.	7.7	254
30	Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget, 2014, 5, 1038-1051.	1.8	248
31	Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma. Journal of Clinical Oncology, 2007, 25, 3357-3361.	1.6	237
32	Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathologica, 2015, 130, 407-417.	7.7	237
33	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	12.8	237
34	A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature, 2021, 592, 463-468.	27.8	232
35	Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. Journal of Neuro-Oncology, 2001, 53, 177-185.	2.9	231
36	Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. Annals of Neurology, 2003, 54, 388-392.	5.3	226

#	Article	IF	CITATIONS
37	Malignant glioma biology: Role for TGF-? in growth, motility, angiogenesis, and immune escape. Microscopy Research and Technique, 2001, 52, 401-410.	2.2	224
38	Trial watch: IDO inhibitors in cancer therapy. Oncolmmunology, 2014, 3, e957994.	4.6	223
39	Prognostic or predictive value of <i>MGMT</i> promoter methylation in gliomas depends on <i>IDH1</i> mutation. Neurology, 2013, 81, 1515-1522.	1.1	211
40	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathologica, 2016, 131, 903-910.	7.7	203
41	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathologica, 2018, 136, 273-291.	7.7	190
42	Angiotensin II sustains brain inflammation in mice via TGF-β. Journal of Clinical Investigation, 2010, 120, 2782-2794.	8.2	177
43	Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathologica, 2014, 128, 561-571.	7.7	176
44	Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene, 2000, 19, 4210-4220.	5.9	159
45	The therapeutic potential of targeting tryptophan catabolism in cancer. British Journal of Cancer, 2020, 122, 30-44.	6.4	159
46	MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Research, 2003, 63, 8996-9006.	0.9	158
47	Acute Stroke in Times of the COVID-19 Pandemic. Stroke, 2020, 51, 2224-2227.	2.0	154
48	mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proceedings of the United States of America, 2014, 111, 409-414.	7.1	152
49	Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. Acta Neuropathologica, 2017, 133, 629-644.	7.7	146
50	New (alternative) temozolomide regimens for the treatment of glioma. Neuro-Oncology, 2009, 11, 69-79.	1.2	142
51	Comprehensive Allelotype and Genetic Analysis of 466 Human Nervous System Tumors. Journal of Neuropathology and Experimental Neurology, 2000, 59, 544-558.	1.7	137
52	Transforming Growth Factors β1 (TGF-β1) and TGF-β2 Promote Glioma Cell Migration via Up-Regulation of αVβ3 Integrin Expression. Biochemical and Biophysical Research Communications, 2000, 268, 607-611.	2.1	130
53	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncology, 2016, 18, now133.	1.2	130
54	Tweety-Homolog 1 Drives Brain Colonization of Gliomas. Journal of Neuroscience, 2017, 37, 6837-6850.	3.6	129

#	Article	IF	CITATIONS
55	Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non–Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 777-787.	5.6	129
56	Costimulatory Protein 4IgB7H3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness. Clinical Cancer Research, 2012, 18, 105-117.	7.0	126
57	The Endogenous Tryptophan Metabolite and NAD+ Precursor Quinolinic Acid Confers Resistance of Gliomas to Oxidative Stress. Cancer Research, 2013, 73, 3225-3234.	0.9	126
58	The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells. PLoS ONE, 2011, 6, e19823.	2.5	126
59	Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nature Reviews Neurology, 2017, 13, 363-374.	10.1	125
60	Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro-Oncology, 2011, 13, 566-579.	1.2	121
61	Iron Induces Anti-tumor Activity in Tumor-Associated Macrophages. Frontiers in Immunology, 2017, 8, 1479.	4.8	121
62	Nanosensor Detection of an Immunoregulatory Tryptophan Influx/Kynurenine Efflux Cycle. PLoS Biology, 2007, 5, e257.	5.6	112
63	Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. Nature Communications, 2020, 11, 931.	12.8	112
64	A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma. Clinical Cancer Research, 2014, 20, 6304-6313.	7.0	111
65	Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas. Nature Cancer, 2021, 2, 723-740.	13.2	110
66	Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without <i>MGMT</i> Promoter Hypermethylation (EORTC 26082). Clinical Cancer Research, 2016, 22, 4797-4806.	7.0	105
67	N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. Neuro-Oncology, 2019, 21, 95-105.	1.2	100
68	Decreased utilization of mental health emergency service during the COVID-19 pandemic. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 377-379.	3.2	99
69	Processing of Immunosuppressive Pro-TGF-β1,2 by Human Glioblastoma Cells Involves Cytoplasmic and Secreted Furin-Like Proteases. Journal of Immunology, 2001, 166, 7238-7243.	0.8	97
70	Structural Basis for Aryl Hydrocarbon Receptor-Mediated Gene Activation. Structure, 2017, 25, 1025-1033.e3.	3.3	95
71	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. Journal of Clinical Oncology, 2021, 39, 3839-3852.	1.6	93
72	In vivo nanoparticle imaging of innate immune cells can serve as a marker of disease severity in a model of multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13227-13232.	7.1	87

#	Article	IF	CITATIONS
73	Ezrin-Dependent Promotion of Glioma Cell Clonogenicity, Motility, and Invasion Mediated by BCL-2 and Transforming Growth Factor-β2. Journal of Neuroscience, 2001, 21, 3360-3368.	3.6	85
74	N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-? release and reduces migration and invasiveness of human malignant glioma cells. International Journal of Cancer, 2001, 93, 53-61.	5.1	84
75	Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma. Journal of Neuroimmunology, 2013, 265, 106-116.	2.3	81
76	Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. Neuro-Oncology, 2018, 20, 367-379.	1.2	79
77	Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro-Oncology, 2013, 15, 1017-1026.	1.2	78
78	Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Neuro-Oncology, 2014, 16, 1630-1638.	1.2	77
79	Accumulation of an Endogenous Tryptophan-Derived Metabolite in Colorectal and Breast Cancers. PLoS ONE, 2015, 10, e0122046.	2.5	76
80	A novel tool to analyze MRI recurrence patterns in glioblastoma. Neuro-Oncology, 2008, 10, 1019-1024.	1.2	74
81	K27M-mutant histone-3 as a novel target for glioma immunotherapy. Oncolmmunology, 2017, 6, e1328340.	4.6	74
82	Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression. Acta Neuropathologica, 2011, 122, 353-365.	7.7	71
83	Bevacizumab does not increase the risk of remote relapse in malignant glioma. Annals of Neurology, 2011, 69, 586-592.	5.3	71
84	Neurological sequelae of cancer immunotherapies and targeted therapies. Lancet Oncology, The, 2016, 17, e529-e541.	10.7	71
85	Multiple sclerosis: trapped in deadly glue. Nature Medicine, 2005, 11, 252-253.	30.7	69
86	Dietary tryptophan links encephalogenicity of autoreactive T cells with gut microbial ecology. Nature Communications, 2019, 10, 4877.	12.8	69
87	Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. Neuro-Oncology, 2019, 21, 837-853.	1.2	66
88	Upregulation of tryptophanyl-tRNA synthethase adapts human cancer cells to nutritional stress caused by tryptophan degradation. OncoImmunology, 2018, 7, e1486353.	4.6	62
89	Current status and future directions of anti-angiogenic therapy for gliomas. Neuro-Oncology, 2016, 18, 315-328.	1.2	61
90	Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro-Oncology, 2021, 23, 356-375.	1.2	59

#	Article	IF	CITATIONS
91	A Suppressive Oligodeoxynucleotide Enhances the Efficacy of Myelin Cocktail/IL-4-Tolerizing DNA Vaccination and Treats Autoimmune Disease. Journal of Immunology, 2005, 175, 6226-6234.	0.8	56
92	Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. Neuro-Oncology, 2013, 15, 1405-1412.	1.2	53
93	Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis. Scientific Reports, 2017, 7, 41271.	3.3	53
94	Concepts in glioma immunotherapy. Cancer Immunology, Immunotherapy, 2016, 65, 1269-1275.	4.2	52
95	Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma. Oncotarget, 2015, 6, 31050-31068.	1.8	52
96	Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study. The Lancet Digital Health, 2021, 3, e784-e794.	12.3	52
97	Microenvironmental Clues for Glioma Immunotherapy. Current Neurology and Neuroscience Reports, 2014, 14, 440.	4.2	51
98	Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway. Glia, 2015, 63, 78-90.	4.9	51
99	The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas. Oncolmmunology, 2016, 5, e1240858.	4.6	51
100	Mouse Mesenchymal Stem Cells Suppress Antigen-Specific TH Cell Immunity Independent of Indoleamine 2,3-Dioxygenase 1 (IDO1). Stem Cells and Development, 2010, 19, 657-668.	2.1	49
101	Tryptophanâ€2,3â€dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptorâ€4. Journal of Neurochemistry, 2016, 136, 1142-1154.	3.9	48
102	Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity?. Journal of Neurochemistry, 2014, 131, 251-264.	3.9	47
103	Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial—study protocol. BMJ Open, 2016, 6, e010956.	1.9	46
104	Diffusion-weighted MRI in transient global amnesia and its diagnostic implications. Neurology, 2020, 95, e206-e212.	1.1	46
105	EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma Journal of Clinical Oncology, 2016, 34, 2001-2001.	1.6	46
106	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Molecular and Cellular Proteomics, 2019, 18, 1255-1268.	3.8	45
107	Protein kinase Cβ as a therapeutic target stabilizing blood–brain barrier disruption in experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 14735-14740.	7.1	43
108	Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib. Clinical Cancer Research, 2019, 25, 253-265.	7.0	42

#	Article	IF	CITATIONS
109	Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. Neuro-Oncology, 2020, 22, 1162-1172.	1.2	42
110	Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor Kinase. PLoS ONE, 2012, 7, e47663.	2.5	42
111	Suppression of human CD4+ T cell activation by 3,4-dimethoxycinnamonyl-anthranilic acid (tranilast) is mediated by CXCL9 and CXCL10. Biochemical Pharmacology, 2011, 82, 632-641.	4.4	41
112	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Molecular and Cellular Proteomics, 2018, 17, 2132-2145.	3.8	41
113	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. , 2021, 9, e002459.		41
114	Correlated magnetic resonance imaging and ultramicroscopy (MR-UM) is a tool kit to assess the dynamics of glioma angiogenesis. ELife, 2016, 5, e11712.	6.0	40
115	Fourier Transform Infrared Microscopy Enables Guidance of Automated Mass Spectrometry Imaging to Predefined Tissue Morphologies. Scientific Reports, 2018, 8, 313.	3.3	37
116	Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. Acta Neuropathologica Communications, 2019, 7, 163.	5.2	37
117	Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy. Oncotarget, 2016, 7, 56713-56725.	1.8	36
118	Driving mesenchymal transition in glioblastoma. Neuro-Oncology, 2020, 22, 1-2.	1.2	36
119	Understanding and Targeting Alkylator Resistance in Glioblastoma. Cancer Discovery, 2014, 4, 1120-1122.	9.4	35
120	Proximity ligation assay evaluates IDH1R132H presentation in gliomas. Journal of Clinical Investigation, 2015, 125, 593-606.	8.2	35
121	Glioblastoma in elderly patients: solid conclusions built on shifting sand?. Neuro-Oncology, 2018, 20, 174-183.	1.2	33
122	Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation—the NCT Neuro Master Match (N2M2) pilot study. Neuro-Oncology, 2018, 20, 826-837.	1.2	32
123	Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma. BMC Cancer, 2011, 11, 127.	2.6	30
124	Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer. Oncolmmunology, 2017, 6, e1274477.	4.6	30
125	Monitoring innate immune cell dynamics in the glioma microenvironment by magnetic resonance imaging and multiphoton microscopy (MR-MPM). Theranostics, 2020, 10, 1873-1883.	10.0	30
126	Tryptophan metabolism in brain tumors — IDO and beyond. Current Opinion in Immunology, 2021, 70, 57-66.	5.5	30

#	Article	IF	CITATIONS
127	Involvement of protein kinase Cl̃´and extracellular signal-regulated kinase-2 in the suppression of microglial inducible nitric oxide synthase expression by N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast). Biochemical Pharmacology, 2003, 66, 1263-1270.	4.4	27
128	Synovial Fibroblasts Selectively Suppress Th1 Cell Responses through IDO1-Mediated Tryptophan Catabolism. Journal of Immunology, 2017, 198, 3109-3117.	0.8	27
129	Shaping the glioma immune microenvironment through tryptophan metabolism. CNS Oncology, 2012, 1, 99-106.	3.0	26
130	Concepts for Immunotherapies in Gliomas. Seminars in Neurology, 2018, 38, 062-072.	1.4	26
131	Geriatric neuro-oncology. Current Opinion in Neurology, 2011, 24, 599-604.	3.6	25
132	CMV infection and glioma, a highly controversial concept struggling in the clinical arena. Neuro-Oncology, 2014, 16, 332-333.	1.2	25
133	Cancer immunotherapy: exploiting neoepitopes. Cell Research, 2015, 25, 887-888.	12.0	25
134	Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma. Molecular Cancer Research, 2018, 16, 767-776.	3.4	25
135	Radiologic progression of glioblastoma under therapy—an exploratory analysis of AVAglio. Neuro-Oncology, 2018, 20, 557-566.	1.2	24
136	Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBPβ. Frontiers in Immunology, 2020, 11, 657.	4.8	24
137	INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies. BMC Cancer, 2020, 20, 523.	2.6	24
138	Long-term dynamics of multiple sclerosis iron rim lesions. Multiple Sclerosis and Related Disorders, 2022, 57, 103340.	2.0	24
139	Mutant IDH1: An immunotherapeutic target in tumors. Oncolmmunology, 2014, 3, e974392.	4.6	23
140	Suppression of Th1 differentiation by tryptophan supplementation in vivo. Amino Acids, 2017, 49, 1169-1175.	2.7	23
141	Dysfunctional dendritic cells limit antigen-specific T cell response in glioma. Neuro-Oncology, 2023, 25, 263-276.	1.2	23
142	The aryl hydrocarbon receptor in tumor immunity. OncoImmunology, 2012, 1, 396-397.	4.6	22
143	Temporal evolution of acute multiple sclerosis lesions on serial sodium (23Na) MRI. Multiple Sclerosis and Related Disorders, 2019, 29, 48-54.	2.0	22
144	General control non-derepressible 2 (GCN2) in T cells controls disease progression of autoimmune neuroinflammation. Journal of Neuroimmunology, 2016, 297, 117-126.	2.3	21

#	Article	IF	CITATIONS
145	Characterization of Contrast-Enhancing and Non-contrast-enhancing Multiple Sclerosis Lesions Using Susceptibility-Weighted Imaging. Frontiers in Neurology, 2019, 10, 1082.	2.4	21
146	A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16) Journal of Clinical Oncology, 2018, 36, 2001-2001.	1.6	21
147	Prognostic relevance of miRNA-155 methylation in anaplastic glioma. Oncotarget, 2016, 7, 82028-82045.	1.8	21
148	The current landscape of immunotherapy for pediatric brain tumors. Nature Cancer, 2022, 3, 11-24.	13.2	21
149	N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) suppresses microglial inducible nitric oxide synthase (iNOS) expression and activity induced by interferon-γ (IFN-γ). British Journal of Pharmacology, 2001, 134, 1279-1284.	5.4	20
150	EGFRvIII vaccine in glioblastoma—InACT-IVe or not ReACTive enough?. Neuro-Oncology, 2017, 19, 1425-1426.	1.2	20
151	Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. Cancer Medicine, 2020, 9, 8373-8385.	2.8	19
152	Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. Radiology, 2020, 297, 164-175.	7.3	19
153	Association of iron rim lesions with brain and cervical cord volume in relapsing multiple sclerosis. European Radiology, 2022, 32, 2012-2022.	4.5	19
154	Treatment of Anaplastic Glioma. Cancer Treatment and Research, 2015, 163, 89-101.	0.5	18
155	Increasing the sensitivity of MRI for the detection of multiple sclerosis lesions by long axial coverage of the spinal cord: a prospective study in 119 patients. Journal of Neurology, 2017, 264, 341-349.	3.6	18
156	Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas. Current Opinion in Oncology, 2018, 30, 368-374.	2.4	18
157	Understanding and Treating Glioblastoma. Neurologic Clinics, 2018, 36, 485-499.	1.8	18
158	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. Clinical Cancer Research, 2022, 28, 585-593.	7.0	18
159	Diffusion-weighted imaging of the dentate nucleus after repeated application of gadolinium-based contrast agents in multiple sclerosis. Magnetic Resonance Imaging, 2019, 58, 1-5.	1.8	17
160	The promises of immunotherapy in gliomas. Current Opinion in Neurology, 2017, 30, 650-658.	3.6	16
161	Correlated MRI and Ultramicroscopy (MR-UM) of Brain Tumors Reveals Vast Heterogeneity of Tumor Infiltration and Neoangiogenesis in Preclinical Models and Human Disease. Frontiers in Neuroscience, 2018, 12, 1004.	2.8	16
162	Tryptophan metabolism is inversely regulated in the tumor and blood of patients with glioblastoma. Theranostics, 2021, 11, 9217-9233.	10.0	16

#	Article	IF	CITATIONS
163	Defective p53 antiangiogenic signaling in glioblastoma. Neuro-Oncology, 2010, 12, 894-907.	1.2	14
164	Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma Journal of Clinical Oncology, 2016, 34, 2019-2019.	1.6	14
165	Interaction between the heart and the brain in transient global amnesia. Journal of Neurology, 2019, 266, 3048-3057.	3.6	13
166	LAPTM5–CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance. Frontiers in Oncology, 2020, 10, 747.	2.8	13
167	A Set of Cell Lines Derived from a Genetic Murine Glioblastoma Model Recapitulates Molecular and Morphological Characteristics of Human Tumors. Cancers, 2021, 13, 230.	3.7	13
168	Central retinal artery occlusion as a neuroâ€ophthalmological emergency: the need to raise public awareness. European Journal of Neurology, 2021, 28, 2111-2114.	3.3	13
169	Radiation therapy and concurrent plus adjuvant temsirolimus (CCI-779) versus chemoirradiation with temozolomide in newly diagnosed glioblastoma without methylation of the <i> MGMT </i> gene promoter Journal of Clinical Oncology, 2014, 32, 2003-2003.	1.6	13
170	AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas. Neurological Research and Practice, 2022, 4, .	2.0	13
171	Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. Acta Neuropathologica, 2017, 133, 325-327.	7.7	12
172	Vaccine Strategies in Gliomas. Current Treatment Options in Neurology, 2018, 20, 11.	1.8	12
173	Single-Cell High-Throughput Technologies in Cerebrospinal Fluid Research and Diagnostics. Frontiers in Immunology, 2019, 10, 1302.	4.8	12
174	Uncompleted emergency department care and discharge against medical advice in patients with neurological complaints: a chart review. BMC Emergency Medicine, 2019, 19, 52.	1.9	12
175	cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma. Journal of Neuro-Oncology, 2020, 146, 9-23.	2.9	12
176	Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma. Journal of Neuro-Oncology, 2014, 117, 85-92.	2.9	11
177	Susceptibilityâ€weighted imaging in malignant melanoma brain metastasis. Journal of Magnetic Resonance Imaging, 2019, 50, 1251-1259.	3.4	11
178	MRI of Iron Oxide Nanoparticles and Myeloperoxidase Activity Links Inflammation to Brain Edema in Experimental Cerebral Malaria. Radiology, 2019, 290, 359-367.	7.3	11
179	Autoimmune diseases and immunosuppressive therapy in relation to the risk of glioma. Cancer Medicine, 2020, 9, 1263-1275.	2.8	11
180	Abstract 4454: Identification of BAY-218, a potent and selective small-molecule AhR inhibitor, as a new modality to counteract tumor immunosuppression. Cancer Research, 2019, 79, 4454-4454.	0.9	11

#	Article	IF	CITATIONS
181	T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas. Clinical Cancer Research, 2022, 28, 378-389.	7.0	11
182	Challenging cytomegalovirus data in glioblastoma. Neuro-Oncology, 2014, 16, 165-165.	1.2	10
183	Spatiotemporal evolution of venous narrowing in acute MS lesions. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e440.	6.0	10
184	Large-scale characterization of the microvascular geometry in development and disease by tissue clearing and quantitative ultramicroscopy. Journal of Cerebral Blood Flow and Metabolism, 2020, 41, 0271678X2096185.	4.3	10
185	Diffusely appearing white matter in multiple sclerosis: Insights from sodium (23Na) MRI. Multiple Sclerosis and Related Disorders, 2021, 49, 102752.	2.0	10
186	Blood–brain barrier and brain edema. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 104, 53-62.	1.8	9
187	Cood maths is needed to understand CMV data in glioblastoma. International Journal of Cancer, 2014, 134, 2991-2992.	5.1	9
188	Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. Neurology, 2019, 92, e2754-e2763.	1.1	9
189	Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. Neuro-Oncology, 2020, 22, 1667-1676.	1.2	9
190	Genetically Modified Cellular Therapies for Malignant Gliomas. International Journal of Molecular Sciences, 2021, 22, 12810.	4.1	9
191	Patient-Derived Tumor Organoids for Guidance of Personalized Drug Therapies in Recurrent Glioblastoma. International Journal of Molecular Sciences, 2022, 23, 6572.	4.1	9
192	Toxicity of teriflunomide in aryl hydrocarbon receptor deficient mice. Biochemical Pharmacology, 2015, 98, 484-492.	4.4	8
193	Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis. Journal of Translational Medicine, 2016, 14, 99.	4.4	8
194	Off-label use of IV t-PA in patients with intracranial neoplasm and cavernoma. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628561775342.	3.5	8
195	Investigation of the "central vein sign―in infratentorial multiple sclerosis lesions. Multiple Sclerosis and Related Disorders, 2020, 45, 102409.	2.0	8
196	Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma. Neuro-Oncology Advances, 2020, 2, vdz060.	0.7	8
197	Characterization of chronic active multiple sclerosis lesions with sodium (²³ Na) magnetic resonance imaging—preliminary observations. European Journal of Neurology, 2021, 28, 2392-2395.	3.3	8
198	Anti-inflammatory strategies for the treatment of multiple sclerosis – tryptophan catabolites may hold the key. Drug Discovery Today: Therapeutic Strategies, 2006, 3, 401-408.	0.5	7

#	Article	IF	CITATIONS
199	HIV-Associated Cerebellar Dysfunction and Improvement with Aminopyridine Therapy: A Case Report. Case Reports in Neurology, 2017, 9, 121-126.	0.7	7
200	Lack of T1 hyperintensity in the dentate nucleus after 15 administrations of a macrocyclic contrast agent in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 324-326.	1.9	7
201	TCR validation toward gene therapy for cancer. Methods in Enzymology, 2019, 629, 419-441.	1.0	7
202	Brain Atrophy in Natalizumabâ€treated Patients with Multiple Sclerosis: A 5â€year Retrospective Study. Journal of Neuroimaging, 2019, 29, 190-192.	2.0	7
203	Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101. Neuro-Oncology Practice, 2022, 9, 310-316.	1.6	7
204	Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions. Multiple Sclerosis Journal, 2022, 28, 2294-2298.	3.0	7
205	Functional MHC Class II Is Upregulated in Neurofibromin-Deficient Schwann Cells. Journal of Investigative Dermatology, 2013, 133, 1372-1375.	0.7	6
206	Normal mast cell numbers in the tissues of AhRâ€deficient mice. Experimental Dermatology, 2016, 25, 62-63.	2.9	6
207	High-throughput discovery of cancer-targeting TCRs. Methods in Enzymology, 2019, 629, 401-417.	1.0	6
208	Hepatocyte-intrinsic type I interferon signaling reprograms metabolism and reveals a novel compensatory mechanism of the tryptophan-kynurenine pathway in viral hepatitis. PLoS Pathogens, 2020, 16, e1008973.	4.7	6
209	Venous Diameter Changes in Chronic Active Multiple Sclerosis Lesions. Journal of Neuroimaging, 2021, 31, 394-400.	2.0	6
210	Hypoxia Routes Tryptophan Homeostasis Towards Increased Tryptamine Production. Frontiers in Immunology, 2021, 12, 590532.	4.8	6
211	Chronobiology of transient global amnesia. Journal of Neurology, 2022, 269, 361-367.	3.6	6
212	Sex-related differences in stressful events precipitating transient global amnesia – A retrospective observational study. Journal of the Neurological Sciences, 2021, 425, 117464.	0.6	6
213	Intrathecal activation of CD8 ⁺ memory T cells in IgG4â€related disease of the brain parenchyma. EMBO Molecular Medicine, 2021, 13, e13953.	6.9	6
214	A mutation-specific peptide vaccine targeting <i>IDH1R132H</i> in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16) Journal of Clinical Oncology, 2016, 34, TPS2082-TPS2082.	1.6	6
215	Simulation, Implementation and Measurement of Defined Sound Fields for Blood–Brain Barrier Opening in Rats. Ultrasound in Medicine and Biology, 2022, 48, 422-436.	1.5	6
216	MRI predictors for the conversion from contrast-enhancing to iron rim multiple sclerosis lesions. Journal of Neurology, 2022, , 1.	3.6	6

#	Article	IF	CITATIONS
217	Spatial distribution of multiple sclerosis iron rim lesions and their impact on disability. Multiple Sclerosis and Related Disorders, 2022, 64, 103967.	2.0	6
218	Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma. Journal of Neuro-Oncology, 2016, 129, 533-539.	2.9	5
219	Nonmeasurable Speckled Contrast-Enhancing Lesions Appearing During Course of Disease Are Associated With IDH Mutation in High-Grade Astrocytoma Patients. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1472-1480.	0.8	5
220	T cells engineered to home in on brain cancer. Nature, 2018, 561, 319-320.	27.8	5
221	Quantitative MRI texture analysis in chronic active multiple sclerosis lesions. Magnetic Resonance Imaging, 2021, 79, 97-102.	1.8	5
222	Treatment standards for direct oral anticoagulants in patients with acute ischemic stroke and non-valvular atrial fibrillation: A survey among German stroke units. PLoS ONE, 2022, 17, e0264122.	2.5	5
223	The aryl hydrocarbon receptor as a promoter of malignant glioma. Cell Cycle, 2012, 11, 643-644.	2.6	4
224	Tregs in gliomas - the jury is still out. Neuro-Oncology, 2015, 17, 769-770.	1.2	4
225	Synergy of vaccination and agonist OX40 treatment—toward a mechanism-driven combination of glioma immunotherapy. Neuro-Oncology, 2018, 20, 4-5.	1.2	4
226	How to integrate immunotherapy into standard of care in glioblastoma. Neuro-Oncology, 2019, 21, 699-700.	1.2	4
227	<p>Changes in Demographic and Diagnostic Spectra of Patients with Neurological Symptoms Presenting to an Emergency Department During the COVID-19 Pandemic: A Retrospective Cohort Study</p> . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2221-2227.	2.2	4
228	<p>Comparing Expert and Non-Expert Assessment of Patients Presenting with Neurological Symptoms to the Emergency Department: A Retrospective Observational Study</p> . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 447-456.	2.2	4
229	MRI topography of lesions related to internuclear ophthalmoplegia in patients with multiple sclerosis or ischemic stroke. Journal of Neuroimaging, 2021, 31, 471-474.	2.0	4
230	Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (N²M²) Journal of Clinical Oncology, 2016, 34, TPS2084-TPS2084.	1.6	4
231	VXM01 phase I study in patients with resectable progression of a glioblastoma Journal of Clinical Oncology, 2017, 35, 2061-2061.	1.6	4
232	Adding Papillomacular Bundle Measurements to Standard Optical Coherence Tomography Does Not Increase Sensitivity to Detect Prior Optic Neuritis in Patients with Multiple Sclerosis. PLoS ONE, 2016, 11, e0155322.	2.5	4
233	Susceptibilityâ€Weighted 3T MRI of the Swallow Tail Sign in Multiple Sclerosis: A Case Control Study. Journal of Neuroimaging, 2020, 30, 766-768.	2.0	3
234	MGMT promoter methylation as a predictive biomarker for response to radiotherapy versus chemotherapy in malignant astrocytomas in the elderly: The NOA-08 trial Journal of Clinical Oncology, 2012, 30, 2000-2000.	1.6	3

#	Article	IF	CITATIONS
235	Mapping the Multiple Myeloma T Cell Landscape By Immunotherapeutic Perturbation Reveals Mechanism and Determinants of Response to Bispecific T Cell Engagers. Blood, 2021, 138, 731-731.	1.4	3
236	The remains of the day: neuropsychological findings in postacute transient global amnesia. Journal of Neurology, 2022, 269, 4764-4771.	3.6	3
237	Acute Corticonuclear Tract Ischemic Stroke with Isolated Central Facial Palsy. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 495-498.	1.6	2
238	Activity-regulated cytoskeleton-associated protein/activity-regulated gene 3.1 (Arc/Arg3.1) enhances dendritic cell vaccination in experimental melanoma. Oncolmmunology, 2021, 10, 1920739.	4.6	2
239	Impaired semantic memory during acute transient global amnesia. Journal of Neuropsychology, 2021, , .	1.4	2
240	Fulminant Cytotoxic Edema in a Patient with Pneumococcal Meningoencephalitis. Journal of Clinical		

#	Article	IF	CITATIONS
253	Aryl hydrocarbon receptor (AhR) regulation of inflammation and cancer. Toxicology Letters, 2013, 221, S29.	0.8	0
254	A3.18â€Synovial Fibroblasts Inhibit Inflammatory T Cell Responses through Tryptophan Metabolism. Annals of the Rheumatic Diseases, 2013, 72, A20.1-A20.	0.9	0
255	Tryptophan-2,3-dioxygenase in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2014, 275, 65.	2.3	0
256	Mutant IDH1R132H bears a mutation-specific CD4 T cell epitope suitable for vaccination of human CNS tumors. Journal of Neuroimmunology, 2014, 275, 39.	2.3	0
257	Inhibition of kynurenine 3-monooxygenase in EAE. Journal of Neuroimmunology, 2014, 275, 127.	2.3	0
258	Impaired remission from autoimmune neuroinflammation upon T cell-specific knockout of the stress kinase GCN2. Journal of Neuroimmunology, 2014, 275, 174.	2.3	0
259	UV irradiation-mediated systemic immune suppression through AHR signalling. Journal of Neuroimmunology, 2014, 275, 128-129.	2.3	0
260	Immunotherapy of Gliomas. , 2018, , 657-664.		0
261	Effect of Glioma N-Myc downstream regulated gene 1 (NDRG1) on the tumor microenvironment Journal of Clinical Oncology, 2016, 34, 11587-11587.	1.6	0
262	IMMU-54. THE ONCOMETABOLITE R-2-HYDROXYGLUTARATE SUPPRESSES THE INNATE IMMUNE MICROENVIRONMENT OF IDH1-MUTATED GLIOMAS VIA ARYL HYDROCARBON RECEPTOR SIGNALING. Neuro-Oncology, 2018, 20, vi133-vi133.	1.2	0
263	IMMU-04. UNVEILING THE TUMOR-METABOLOME-IMMUNITY AXIS OF GLIOMA. Neuro-Oncology, 2021, 23, vi92-vi92.	1.2	0
264	PATH-39. INTEGRATED MOLECULAR-MORPHOLOGICAL MENINGIOMA CLASSIFICATION: A MULTICENTER RETROSPECTIVE ANALYSIS, RETRO- AND PROSPECTIVELY VALIDATED. Neuro-Oncology, 2021, 23, vi123-vi124.	1.2	0
265	How mutant isocitrate dehydrogenase orchestrates immune cells. Neuro-Oncology, 2022, 24, 210-212.	1.2	0